Holen Sie sich die Stockscreener-App
44.22
1.73%
0.75
Handel nachbörslich:
44.22
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$43.47
Offen:
$43.48
24-Stunden-Volumen:
1.45M
Relative Volume:
1.97
Marktkapitalisierung:
$4.08B
Einnahmen:
$522.75M
Nettoeinkommen (Verlust:
$-558.99M
KGV:
-4.9298
EPS:
-8.97
Netto-Cashflow:
$-439.53M
1W Leistung:
-3.41%
1M Leistung:
-4.70%
6M Leistung:
+16.31%
1J Leistung:
-2.58%
1-Tages-Spanne:
$42.85
$44.45
1-Wochen-Bereich:
$41.45
$46.75
52-Wochen-Spanne:
$37.02
$60.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Firmenname
Ultragenyx Pharmaceutical Inc
Sektor
Branche
Telefon
415-483-8800
Adresse
60 LEVERONI COURT, NOVATO, CA
Vergleichen Sie RARE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
44.22 | 4.08B | 522.75M | -558.99M | -439.53M | -6.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-06 | Hochstufung | Goldman | Neutral → Buy |
| 2024-04-22 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-06-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-04-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-12-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-11-03 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-08-01 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-03-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-19 | Eingeleitet | UBS | Sell |
| 2021-07-15 | Eingeleitet | Guggenheim | Neutral |
| 2021-06-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-05-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-05-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-02 | Fortgesetzt | Stifel | Buy |
| 2021-02-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-11-24 | Fortgesetzt | Evercore ISI | In-line |
| 2020-11-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2019-08-02 | Fortgesetzt | Wedbush | Outperform |
| 2019-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-05-10 | Eingeleitet | Goldman | Neutral |
| 2018-04-18 | Hochstufung | SunTrust | Hold → Buy |
| 2018-03-22 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-21 | Bestätigt | Stifel | Buy |
| 2018-01-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-01-18 | Eingeleitet | Credit Suisse | Outperform |
| 2017-12-05 | Bestätigt | Barclays | Equal Weight |
| 2017-12-04 | Hochstufung | Jefferies | Hold → Buy |
| 2017-09-14 | Hochstufung | Wedbush | Neutral → Outperform |
Alle ansehen
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Franklin Resources Inc. Decreases Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Ultragenyx Awards Key Employee Stock Grants: 15,175 RSUs Distributed in Strategic Talent Acquisition - StockTitan
RARE Submits BLA To The FDA For Sanfilippo Syndrome Gene Therapy - Barchart
RARE Submits BLA to the FDA for Sanfilippo Syndrome Gene Therapy - Zacks Investment Research
Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $88.00 Price Target at Wells Fargo & Company - MarketBeat
Expert Outlook: Ultragenyx Pharmaceutical Through The Eyes Of 11 Analysts - Benzinga
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by Geode Capital Management LLC - MarketBeat
Ultragenyx seeks FDA nod for Sanfilippo A gene therapy By Investing.com - Investing.com Canada
NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible - GlobeNewswire
Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome - GlobeNewswire
Ultragenyx Launches Pivotal Phase 3 Trial for Breakthrough Angelman Syndrome Treatment GTX-102 - StockTitan
Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight - GlobeNewswire Inc.
Ultragenyx seeks FDA nod for Sanfilippo A gene therapy - Investing.com
Ultragenyx Submits Biologics License Application to the - GlobeNewswire
Ultragenyx Seeks FDA Approval for Groundbreaking Sanfilippo Syndrome Gene Therapy - StockTitan
Ultragenyx Pharmaceutical Inc. Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA) - Marketscreener.com
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
State Street Corp Has $147.99 Million Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx Pharmaceutical's SWOT analysis: rare disease biotech stock at crossroads - Investing.com
Y Intercept Hong Kong Ltd Buys 12,617 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Janus Henderson Group PLC Sells 35,200 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Hypophosphatasia Market Expected to Experience Major Growth by 2034, According to DelveInsight | PuREC, AstraZeneca, Ultragenyx Pharma Inc., Alexion - The Globe and Mail
Hypophosphatasia Market Expected to Experience Major Growth - openPR
Frazier Life Sciences Management L.P. Purchases 208,715 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
CDKL5 Deficiency Disorder Pipeline 2024: Clinical Trials - openPR
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Position Reduced by Wellington Management Group LLP - MarketBeat
BNP Paribas Financial Markets Sells 38,641 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Opinion: What Accelerated Approval’s Naysayers Miss - BioSpace
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Position Reduced by Jacobs Levy Equity Management Inc. - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by Point72 Asset Management L.P. - MarketBeat
Point72 DIFC Ltd Has $806,000 Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
(RARE) On The My Stocks Page - Stock Traders Daily
Ultragenyx (RARE) Down 6.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance Australia
RTW Investments LP Lowers Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Possible Bearish Signals With Ultragenyx Pharmaceutical Insiders Disposing Stock - Simply Wall St
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Position Lessened by Cinctive Capital Management LP - MarketBeat
Bamco Inc. NY Purchases New Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Erste Asset Management GmbH Makes New Investment in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Verition Fund Management LLC Reduces Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by Charles Schwab Investment Management Inc. - MarketBeat
Cerity Partners LLC Invests $1.77 Million in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Baker BROS. Advisors LP Has $87.55 Million Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Capstone Investment Advisors LLC Purchases Shares of 13,089 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Vestal Point Capital LP Decreases Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Suvretta Capital Management LLC Sells 910,112 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Alkeon Capital Management LLC Boosts Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Acuta Capital Partners LLC Purchases New Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx to Participate in Investor Conferences in December - GlobeNewswire
Ultragenyx to Present at Three Major Healthcare Investor Conferences in December | RARE Stock News - StockTitan
CDKL5 Deficiency Disorder Market Revenue to Expand Significantly by 2034, States DelveInsight Report | Marinus Pharma, Takeda, Zogenix, Inc., UCB, Ultragenyx Pharma - The Globe and Mail
Finanzdaten der Ultragenyx Pharmaceutical Inc-Aktie (RARE)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):